Mirvaso Derm (brimonidine) gel

Mirvaso Derm (brimonidine) gel

SKU:2718
To favorites
Mirvaso Derm (brimonidine) gel treatment of facial erythema with rosacea
Active substance:brimonidine
Pharmacological group:Dermatology
Formulation:Gel
Dosage mg:0.5
In stock
$94
11
Description
Features
Reviews

Instructions for Mirvaso Derm (brimonidine) gel

English Product Name
Mirvaso Derm

Release Form
Gel for external use

Description Mirvaso Derm
Gel for external use 0.5% white to light yellow, opaque.

1 g
brimonidine tartrate 5 mg
Auxiliary substances: carbomer - 12.5 mg, methylparahydroxybenzoate - 1 mg, phenoxyethanol - 4 mg, glycerol - 55 mg, titanium dioxide - 0.625 mg, propylene glycol - 55 mg, sodium hydroxide - up to pH 6.0, purified water - up to 1000 mg.

10 g - plastic laminated tubes (1) - cardboard packs.
30 g - plastic laminated tubes (1) - cardboard packs.

ATX codes
D11AX21 Brimonidine

Clinical and pharmacological groups / Group affiliation
Selective alpha<SUB>2</SUB>-agonist for rosacea

Active ingredient
brimonidine tartrate

Pharmacotherapeutic group: Mirvaso Derm

the inventive agent for treating facial erythema in rosacea is a selective alpha2-adrenomimetic.

Pharmacological effect:

said agent is intended for external use and is a highly selective agonist of α2-adrenergic receptors. Its affinity for α2-adrenergic receptors is 1000 times that of α1-adrenergic receptors. Applying a highly selective α2-adrenergic agonist to the facial skin reduces erythema by direct vasoconstriction of the small blood vessels of the dermis.

Pharmacotherapeutic group Mirvaso Derm:

the inventive agent for treating facial erythema in rosacea is a selective alpha2-adrenomimetic.

Pharmacological effect Mirvaso Derm:

said agent is intended for external use and is a highly selective agonist of α2-adrenergic receptors. Its affinity for α2-adrenergic receptors is 1000 times that of α1-adrenergic receptors. Applying a highly selective α2-adrenergic agonist to the facial skin reduces erythema by direct vasoconstriction of the small blood vessels of the dermis.

Indications Mirvaso Derm

it is recommended for the treatment of facial erythema in rosacea.

Method of application, course and dosage:

this product is intended for external use only. Apply a thin layer on the skin of each of the 5 facial areas (forehead, chin, nose, cheeks) once a day if erythema is present. The maximum recommended daily dose is 1 g (roughly equal to 5 match heads).

Features
Active substance
Pharmacological group
Formulation
Dosage mg
Pills in 1 package
Country of origin
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating